Drug Profile
ABI H2158
Alternative Names: 2158; ABI-2158; ABI-H2158Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Indiana University
- Developer Assembly Biosciences; Indiana University
- Class Antivirals; Small molecules
- Mechanism of Action Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 31 Dec 2023 BeiGene receives a termination notice from Assembly Biosciences for License and Collaboration Agreement in China for development and commercialisation of ABI H0731, ABI H2158, and ABI H3733
- 01 Sep 2021 Discontinued - Phase-II for Hepatitis B (Combination therapy, Treatment-naive) in United Kingdom, Taiwan, South Korea, Hong Kong, China, Canada, Australia, USA and New Zealand (PO) (NCT04398134)
- 01 Sep 2021 Discontinued - Phase-I for Hepatitis B (In volunteers) in Australia (PO)